X4 Pharmaceuticals, Inc (XFOR) › Cash & EquivalentsX4 Pharmaceuticals, Inc (XFOR) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2016: $15.16M2017: $26.68M2018: $8.13M2019: $126.18M2020: $78.71M2021: $81.79M2022: $121.72M2023: $99.22M2024: $55.70M2025: $217.05M$217.05M2016Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$217.05M+289.7%2024$55.70M-43.9%2023$99.22M-18.5%2022$121.72M+48.8%2021$81.79M+3.9%2020$78.71M-37.6%2019$126.18M+1451.3%2018$8.13M-69.5%2017$26.68M+76.0%2016$15.16M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share